<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630266</url>
  </required_header>
  <id_info>
    <org_study_id>47-1389</org_study_id>
    <nct_id>NCT00630266</nct_id>
  </id_info>
  <brief_title>Confirmation Trial of the Acorn CorCap Cardiac Support Device (CSD) at the Same Time as Mitral Valve Repair</brief_title>
  <acronym>MVR + CorCap</acronym>
  <official_title>Clinical Evaluation of Acorn CorCap Cardiac Support Device Concomitant to MVR - A Confirmatory Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorn Cardiovascular, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorn Cardiovascular, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to evaluate patients when they have an Acorn CorCapTM Cardiac
      Support Device (CSD) placed around their heart for the treatment of heart failure at the same
      time as their mitral valve surgery.

      The CorCapTM CSD is intended to support the heart, potentially preventing further dilation
      that is associated with progressive heart failure, thereby potentially preserving or
      improving heart function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Acorn CorCap Cardiac Support Device (CSD) is a new therapy for the treatment of heart
      failure that is designed to reduce left ventricular dilation, which is one of the most
      important pathophysiological mechanisms underlying the clinical syndrome of heart failure.
      The Acorn CorCap CSD is intended to reduce wall stress and support the heart, in order to
      prevent further dilation that is associated with progressive heart failure. It is designed to
      result in reduced left ventricular size and improve left ventricluar function, which should
      result in improved patient functional status.

      The purpose of the study is to provide confirmatory data to demonstrate an improved
      benefit-risk profile in support of a Pre-Market Approval (PMA) application for the Acorn
      CorCap CSD when placed concomitant to Mitral Valve Repair/Replacement (MVR).

      The primary efficacy objective is to evaluate patient functional status after 6 months of
      follow-up. The safety endpoint is perioperative (30 day) mortality.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patient functional status as evaluated using the Minnesota Living with Heart Failure questionnaire</measure>
    <time_frame>6 month follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in maximal exercise tolerance evaluated using cardiopulmonary exercise (CPX) testing (peak VO2 exercise test)</measure>
    <time_frame>6 Month follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sub-maximal exercise tolerance as evaluated using the Six Minute Walk test.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who have died (all-cause) or had a re-hospitalization due to heart failure.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peri-operative mortality, death occuring within 30 days of baseline surgery.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of death and SAEs overall and for each specific type of event</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient functional status as evaluated using the Minnesota Living with Heart Failure Questionnaire</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorCap CSD</intervention_name>
    <description>The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dilated cardiomyopathy of either ischemic or non-ischemic origin

          -  Patients must be on stable, optimally uptitrated medical therapy recommended according
             to current guidelines as standard of care of heart failure therapy in the United
             States. This minimally includes:

               1. Angiotensin-converting enzyme inhibitors (ACE) or alternate if ACE not tolerated
                  for greater than or equal to 1 month prior to enrollment (not required for
                  patients with a mitral valve anomaly that is not likely to respond to medication
                  and requires surgical intervention).

               2. Treatment with a beta-blocker, unless intolerant, for greater than or equal to 3
                  months prior to enrollment (not required for patients with a mitral valve anomaly
                  that is not likely to respond to medication and requires surgical intervention).

               3. Diuretic at least &quot;prn&quot; (as occasion requires).

               4. Cardiac medications unchanged for greater than or equal to 1 month except for
                  diuretic adjustments (not required for patients with a mitral valve anomaly that
                  is not likely to respond to medications and requires surgical intervention).

          -  Adult (18 to 80 years).

          -  Indexed left ventricular end diastolic dimension (LVEDDi)between 30 mm/m2 and 40 mm/m2
             as determined by transthoracic echocardiography.

          -  Mitral regurgitation (MR) greater than or equal to 2+ and scheduled for mitral valve
             repair or replacement. Concomitant tricuspid valve repair or replacement (TVR) and/or
             atrial fibrillation ablation procedures will be permitted.

          -  Left ventricular ejection fraction (LVEF) less than or equal to 45 percent via
             transthoracic echocardiography, cardiac catheterization, radionuclide scan, or
             magnetic resonance imaging

          -  New York Heart Association Functional Class (NYHA) II, III or IV

          -  Geographically available for follow-up

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Inability to reach maximal effort CPX test as defined by the CPX Core Lab

          -  Planned cardiac surgical procedure other than MVR

          -  Hypertrophic obstructive cardiomyopathy.

          -  Significant cardiomegaly, which is estimated to exceed the largest available size of
             CorCap CSD.

          -  Expectation of existing cardiothoracic adhesions that would cause an inability to gain
             complete circumferential access to the heart.

          -  Existing patent CABG.

          -  Candidates for surgical revascularization as determined by an angiogram. Patients with
             ischemic heart disease who have not had an angiogram within the past 3 years and in
             whom lesions amenable to revascularization cannot be excluded should have a repeat
             angiogram.

          -  Any condition considered a contraindication for extracorporeal circulation.

          -  Use of Intra aortic Balloon Pump (IABP), intravenous inotropic or vasoactive agents
             within 30 days prior to enrollment. Pre-operative hemodynamic optimization with IABP,
             IV inotropes or vasoactive agents may be permitted if it is scheduled to occur within
             48 hours of planned index surgery.

          -  Current or anticipated need for left ventricular assist device (LVAD) or cardiac
             replacement device.

          -  Anticipated need for heart transplant within the next two years.

          -  Acute myocardial infarction (AMI), unstable angina, or cerebral vascular accident
             (CVA) or Transient Ischemic Attack (TIA) within past 3 months.

          -  Percutaneous coronary intervention (PCI) or transmyocardial laser revascularization
             (TMR or PMR) within the past 3 months.

          -  Presence of arrhythmias causing hemodynamic instability, history of resuscitated
             sudden death without subsequent treatment with implantable defibrillator or
             amiodarone, or atrial fibrillation with a ventricular rate greater than 100 bpm on
             medication.

          -  Co-morbid condition that reduces life expectancy to less than 1 year.

          -  Active infection.

          -  Pregnancy at the time of enrollment. (Women of child bearing potential must have a
             negative serum pregnancy test within two weeks prior to enrollment, or be using
             hormonal contraceptives or intrauterine devices.)

          -  Enrolled in another investigational study that would confound interpretation of trial
             results.

          -  Patients who participated as control patients in the previous CorCap PMA randomized
             trial.

          -  Unable to comply with protocol-required follow-up (as judged by primary investigator
             or referring cardiologist).

          -  Late stage heart failure with increased surgical risk as defined by the presence of
             four or more of the following:

               1. LVEDD greater than 80 mm/m2

               2. Resting systolic blood pressure (BP) less than or equal to 80 mm Hg (on clinical
                  exam)

               3. Atrial fibrillation at time of enrollment or paced rhythm with underlying atrial
                  fibrillation

               4. Heart failure greater than or equal to 8 years

               5. 6 minute walk less than or equal to 350 meters (1148 feet)

               6. POV2 less than or equal to 13 ml/kg/min (CPX test)

               7. Exercise induced increase in systolic BP less than 10 percent (CPX test)

               8. Previous cardiac surgery

               9. BUN greater than 100 mg/dl

              10. Cachexia (clinical impression)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven F Bolling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A Acker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of the University of Pennsylvania, Cardiovascular Medicine; Penn-Presbyterian Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Pompili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente Northern California Heart Transplant Program</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Wudel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nebraska Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall Starling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark J Zucker, MD, JD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newark Beth Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renzo Cecere, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Hospital, McGill University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pat Pappas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advocate Christ Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Brewer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Cope, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Raines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BryanLGH Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meegan Anderson, RN, BSN, MBA, CCRA</last_name>
    <phone>651-260-4822</phone>
    <email>meegan.anderson@acorncv.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Permanente Northern California Heart Transplant Program</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lockyer, RN (CAP)</last_name>
      <phone>408-851-3826</phone>
      <email>patricia.lockyer@kp.org</email>
    </contact>
    <investigator>
      <last_name>Dana Weisshaar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Pompili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vic Melikian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jay LaBourene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Ansari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Gallagher, RN, BSN</last_name>
      <phone>708-346-4044</phone>
      <phone_ext>27</phone_ext>
      <email>colleen.gallagher@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Pat Pappas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antone Tatooles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5864</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathie Bloem</last_name>
      <phone>734-615-6170</phone>
      <email>bloem@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Steven F Bolling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Leszczynski, RN</last_name>
      <phone>313-916-3520</phone>
      <email>kleszcz1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Robert Brewer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hassan W. Nemeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Czerska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BryanLGH Medical Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Harre, RN</last_name>
      <phone>402-483-3373</phone>
      <email>shari@bhi-1.com</email>
    </contact>
    <investigator>
      <last_name>Edward Raines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Krueger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Baehr, LPN</last_name>
      <phone>402-328-3939</phone>
      <email>dbaehr@neheart.com</email>
    </contact>
    <investigator>
      <last_name>James Wudel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deepak Gangahar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaliprasad N Ayala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Adams, RN</last_name>
      <phone>973-926-8451</phone>
      <email>ladams@sbhcs.com</email>
    </contact>
    <investigator>
      <last_name>Mark J Zucker, MD, JD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Camacho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravi Karanam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Baran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barb Gus, RN</last_name>
      <phone>216-445-6552</phone>
      <email>gusb@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Randall Starling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Smedira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Bowman, RN, BS, CCRC</last_name>
      <phone>717-290-6681</phone>
      <phone_ext>203</phone_ext>
      <email>lbowman@lancasterheart.org</email>
    </contact>
    <investigator>
      <last_name>Jeff Cope, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roy Small, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica L Howard</last_name>
      <phone>215-410-6987</phone>
      <email>jessica.howard@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael A Acker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariell Jessup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Y. Joseph Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PENN-Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha R. Watts, RN, BSN</last_name>
      <phone>215-662-9595</phone>
      <email>marsha.watts@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Michael A. Acker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Y. Joseph Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>W. Clark Hargrove, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohinton Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wilson Szeto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross Zimmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital, McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene Barber, RN</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>36764</phone_ext>
      <email>charlene.barber@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Renzo Cecere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Giannetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>June 16, 2009</last_update_submitted>
  <last_update_submitted_qc>June 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Steve Anderson, President</name_title>
    <organization>Acorn Cardiovascular</organization>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>left ventricular dilation</keyword>
  <keyword>mitral valve repair</keyword>
  <keyword>mitral valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

